Clinicians at Piedmont Heart Institute at Piedmont Atlanta Hospital performed the first HighLife Trans-septal Mitral Valve Replacement in the United States on July 13, as part of an early feasibility trial, according to a press release.
This technique is used to treat patients with a condition called mitral valve insufficiency or regurgitation. The procedure uses a minimally invasive, transcatheter technique and offers patients the possibility of an effective treatment with a quicker recovery compared to cardiac surgery.
“The patient did very well and was discharged home on Day Four and continues to do well at 30 days,” said Dr. Pradeep K. Yadav, Structural Interventional Cardiologist at the Marcus Heart Valve Center.
The HighLife trans-septal MVR system is made of two implants, a valve and a ring, implanted between the left atrium and the left ventricle of the heart through small accesses in the groin. The procedure leaves the patient’s chest unopened and is done on a beating heart guided by an echocardiogram.
“There remains a great need in the Southeast to provide patients with superlative care in valve therapies,” said Dr. Vinod H. Thourani, Chief of Cardiovascular Surgery for Piedmont Healthcare and Marcus Heart Valve Center.
The procedure was performed in the newly constructed Marcus Tower at Piedmont Atlanta by Piedmont structural interventionalists, cardiac surgeons, imaging cardiologists, cardiac catheterization laboratory staff, cardiovascular research staff, Piedmont Heart’s multimedia team, and HighLife Medical’s Therapy Development team.
Information: piedmont.org
About the Author
